Clinical Trial

Research Into the Expression of the csgA-gene and How it Changes in Patients With Parkinson's Disease

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 19, 2026 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study seeks to understand the prevalence and variability of a gut bacteria gene called csgA in people with Parkinson's Disease. This understanding could inform development of potential new therapies targeting the gut in Parkinson's Disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-14; most recent amendment 2026-02-16.
Trial Details
NCT Number NCT07175922
Lead Sponsor Vertero Therapeutics
Conditions Parkinsons Disease (PD)
Enrollment 200 participants
Start Date 2025-09-25
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-19